CELLERITAS Trademark

Trademark Overview


On Wednesday, November 30, 2022, a trademark application was filed for CELLERITAS with the United States Patent and Trademark Office. The USPTO has given the CELLERITAS trademark a serial number of 97697528. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Monday, October 21, 2024. This trademark is owned by CENTER FOR BREAKTHROUGH MEDICINES HOLDINGS, LLC. The CELLERITAS trademark is filed in the Treatment & Processing of Materials Services and Computer & Software Services & Scientific Services categories with the following description:

Manufacturing services for others in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals, plasmid DNA production; manufacturing services for others in the fields of mammalian cell banks, plasmids, adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; manufacturing process consulting

Research and development services in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; consulting services in the fields of research and development for gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; research and development of new products for others; process development services in the nature of research and development of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; scientific research and technical research services, namely, production of cell lines for others using lentivirus technology; scientific research and technical research services relating to producing, assaying and purifying recombinant or manipulated lentivirus; Scientific and technical consulting services relating to producing, assaying, and purifying adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and...
celleritas

General Information


Serial Number97697528
Word MarkCELLERITAS
Filing DateWednesday, November 30, 2022
Status731 - SECOND EXTENSION - GRANTED
Status DateMonday, October 21, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 17, 2023

Trademark Statements


Goods and ServicesManufacturing services for others in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals, plasmid DNA production; manufacturing services for others in the fields of mammalian cell banks, plasmids, adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; manufacturing process consulting
Goods and ServicesResearch and development services in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; consulting services in the fields of research and development for gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; research and development of new products for others; process development services in the nature of research and development of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; scientific research and technical research services, namely, production of cell lines for others using lentivirus technology; scientific research and technical research services relating to producing, assaying and purifying recombinant or manipulated lentivirus; Scientific and technical consulting services relating to producing, assaying, and purifying adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in humans and animals; advisory services relating to research and development of gene therapy products and biopharmaceuticals; manufacturing support services for others, namely, cGMP (Current Good Manufacturing Practice) quality control testing in support of biopharmaceutical development and manufacturing; quality control for others; quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, in the fields of gene therapy, modified gene therapy, cell therapy, tissue engineering and biopharmaceuticals; material testing; product quality testing; scientific laboratory services; scientific research; research and development in the field of gene therapy acceleration, vector genome copy titers, droplet digital polymerase chain reaction (PCR) and digital polymerase chain reaction (PCR), mass spectrometry, capsid characterization, bioassays, plasmid DNA, and analytics testing in the field of genes and gene therapy

Classification Information


International Class040 - Treatment of materials.
US Class Codes100, 103, 106
Class Status Code6 - Active
Class Status DateThursday, December 22, 2022
Primary Code040
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, December 22, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCENTER FOR BREAKTHROUGH MEDICINES HOLDINGS, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressKING OF PRUSSIA, PA 19406

Party NameCENTER FOR BREAKTHROUGH MEDICINES HOLDINGS, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressKING OF PRUSSIA, PA 19406

Trademark Events


Event DateEvent Description
Saturday, December 3, 2022NEW APPLICATION ENTERED
Thursday, December 22, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, September 9, 2023ASSIGNED TO EXAMINER
Thursday, September 14, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 27, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, October 17, 2023PUBLISHED FOR OPPOSITION
Tuesday, October 17, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 12, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, May 9, 2024SOU EXTENSION 1 GRANTED
Thursday, May 9, 2024SOU TEAS EXTENSION RECEIVED
Thursday, May 9, 2024SOU EXTENSION 1 FILED
Friday, May 10, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 21, 2024SOU TEAS EXTENSION RECEIVED
Monday, October 21, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 21, 2024SOU EXTENSION 2 FILED
Monday, October 21, 2024SOU EXTENSION 2 GRANTED